Headquartered in Louisville, CO Fiscal year ends December NASDAQ: BDSX biodesix.com
Biodesix is a diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease. The company operates two primary business lines: Diagnostic Testing and Development Services. Its Diagnostic Tests include the Nodify Lung Nodule Risk Assessment test, which helps clinicians evaluate the risk of lung nodules, and the IQLung Cancer Treatment Guidance test, which supports personalized treatment decisions for lung cancer patients. Both tests are blood-based diagnostics. The Development Services segment partners with biopharmaceutical companies, life sciences organizations, and research institutions, providing scientific, technological, and operational capabilities to support the development of diagnostic tests, tools, and therapeutics. The company trades on Nasdaq under the ticker BDSX. Updated
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
Biodesix is a diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease. The company operates two primary business lines: Diagnostic Testing and Development Services.
The Wall Street consensus 12-month price target for BDSX is $37.33.
